|View printer-friendly version|
|June 02, 2000 3:25 p.m.|
|Teva Pharmaceutical Industries Ltd. Announces Copaxone® Recommended for Approval in the U.K. a Major Step Towards the Approval in the E.U.|
Jerusalem, Israel, June 2, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that Copaxone® (glatiramer acetate for injection) has been recommended for approval for the treatment of relapsing-remitting multiple sclerosis (RR MS) by the Licensing Authority in the U.K. It is anticipated that a marketing authorization will be issued shortly.